References
- 1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-2749.
- 2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–4011
- 3. Lukola, R. Punnonen, Interaction of serine protease inhibitors and substrates with human uterine estrogen receptor, Biochem. Biophys. Res. Commun. 108 (1982) 822–827. doi:10.1016/0006-291X(82)90903-2.
- 4. N. Xu, S. Kwon, D.H. Abbott, D.H. Geller, D.A. Dumesic, R. Azziz, X. Guo, M.O. Goodarzi, Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys, PLoS One. 6 (2011). doi:10.1371/journal.pone.0027286.
- 5. M. Kokosar, A. Benrick, A. Perfilyev, R. Fornes, E. Nilsson, M. Maliqueo, C.J. Behre, A. Sazonova, C. Ohlsson, C. Ling, E. Stener-Victorin, Epigenetic and Transcriptional Alterations in Human Adipose Tissue of Polycystic Ovary Syndrome, Sci. Rep. 6 (2016). doi:10.1038/srep22883.
- 6. J. Boberg, C. Taxvig, S. Christiansen, U. Hass, Possible endocrine disrupting effects of parabens and their metabolites., Reprod. Toxicol. 30 (2010) 301–12. doi:10.1016/j.reprotox.2010.03.011.
- 7. S. Özen, Ş. Darcan, Effects of environmental endocrine disruptors on pubertal development., J. Clin. Res. Pediatr.Endocrinol. 3 (2011) 1–6. doi:10.4274/jcrpe.v3i1.01.
- 8. Konieczna, A. Rutkowska, D. Rachoń, Health risk of exposure to Bisphenol A (BPA)., Rocz. Państwowego Zakładu Hig. 66 (2015) 5–11. http://www.ncbi.nlm.nih.gov/pubmed/25813067 (accessed August 5, 2015).
- 9. G.O. Noonan, L.K. Ackerman, T.H. Begley, Concentration of bisphenol A in highly consumed canned foods on the U.S. market., J. Agric. Food Chem. 59 (2011) 7178–85. doi:10.1021/jf201076f.
- 10. S. De Coster, N. van Larebeke, Endocrine-disrupting chemicals: associated disorders and mechanisms of action., J. Environ. Public Health. 2012 (2012) 713696. doi:10.1155/2012/713696.
- 11. S. Patel, Fragrance compounds: The wolves in sheep’s clothings, Med. Hypotheses. 102 (2017) 106–111. doi:10.1016/j.mehy.2017.03.025.
- 12. Y.A. Lee, E.J. Cho, T. Yokozawa, Protective effect of persimmon (Diospyros kaki) peel proanthocyanidin against oxidative damage under H2O2-induced cellular senescence., Biol. Pharm. Bull. 31 (2008) 1265–9. http://www.ncbi.nlm.nih.gov/pubmed/18520066 (accessed October 7, 2016).
- 13. S. Patel, S. Patel, Analysis of Ebola virus polymerase domains to find strain-specific differences and to gain insight on their pathogenicity, VirusDisease. 27 (2016) 242–250. doi:10.1007/s13337-016-0334-8.
- 14. E.Y. Roh, J.H. Yoon, E.Y. Song, J.J. Kim, K.R. Hwang, S.H. Seo, S. Shin, Single nucleotide polymorphisms in the TGF-β1 gene are associated with polycystic ovary syndrome susceptibility and characteristics: a study in Korean women, J. Assist. Reprod. Genet. 34 (2017) 139–147. doi:10.1007/s10815-016-0824-z.
- 15. J.B. Wu, J.F. Zhai, J. Yang, Role of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in polycystic ovary syndrome risk, Genet. Mol. Res. 15 (2016). doi:10.4238/gmr15048570.
- 16. S. Dasgupta, P.V.S. Sirisha, K. Neelaveni, K. Anuradha, G. Sudhakar, B.M. Reddy, Role of luteinizing hormone β-subunit gene variants among South Indian women with polycystic ovary syndrome, Gene. 494 (2012) 51-56. doi:10.1016/j.gene.2011.11.054.
- 17. Mohamed-Hussein ZA, Harun S. Construction of a polycystic ovarian syndrome (PCOS) pathway based on the interactions of PCOS-related proteins retrieved from bibliomic data. Theor Biol Med Model. 2009;6(1):18.
- 18. The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19:41–47.
- 19. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam Criteria. J Clin Endocrinol Metab. 2006;91:786-789.
- 20. Apter D, Bützow T, Laughlin GA, Yen SS. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab. 1994;79(1):119–125
- 21. Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, Azziz R. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016;106(6):1510–1520.e2.
- 22. Pache TD, Fauser BC. Polycystic ovaries in female-tomale transsexuals. Clin Endocrinol (Oxf). 1993;39(6):702–703.
- 23. Anderson RA, McLaughlin M, Wallace WH, Albertini DF, Telfer EE. The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence. Hum Reprod. 2014;29(1):97–106.
- 24. Gaytan F, Morales C, Leon S, Garcia-Galiano D, Roa J, Tena-Sempere M. Crowding and follicular fate: spatial determinants of follicular reserve and activation of follicular growth in the mammalian ovary. PLoS One. 2015;10(12):e0144099. [
- 25. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod. 2006;21(9):2223–2227.
- 26. Xu J, Bishop CV, Lawson MS, Park BS, Xu F. Anti- Müllerian hormone promotes pre-antral follicle growth, but inhibits antral follicle maturation and dominant follicle selection in primates. Hum Reprod. 2016;31(7):1522–1530.
- 27. Dumont A, Robin G, Dewailly D. Anti-Müllerian hormone in the pathophysiology and diagnosis of polycystic ovarian syndrome. Curr Opin Endocrinol Diabetes Obes. 2018;25(6):377–384.
- 28. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab. 1998;83(7):2479–2485.
- 29. Harlow CR, Shaw HJ, Hillier SG, Hodges JK. Factors influencing follicle-stimulating hormone-responsive steroidogenesis in marmoset granulosa cells: effects of androgens and the stage of follicular maturity. Endocrinology. 1988;122(6):2780–2787.
- 30. Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol. 2010;24(7):1393–1403.
- 31. Кeppesen JV, Kristensen SG, Nielsen ME, Humaidan P, Dal Canto M, Fadini R, Schmidt KT, Ernst E, Yding Andersen C. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol Metab. 2012;97(8):E1524–E1531.
- 32. Kristensen SG, Mamsen LS, Jeppesen JV, Bøtkjær JA, Pors SE, Borgbo T, Ernst E, Macklon KT, Andersen CY. Hallmarks of human small antral follicle development: implications for regulation of ovarian steroidogenesis and selection of the dominant follicle. Front Endocrinol (Lausanne). 2018;8:376.
- 33. Franks S, Hardy K. Androgen action in the ovary. Front Endocrinol (Lausanne). 2018;9:452.
- 34. Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, Franks S. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362(9389):1017–1021.
- 35. Maciel GA, Baracat EC, Benda JA, Markham SM, Hensinger K, Chang RJ, Erickson GF. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(11):5321–5327.
- 36. Homer MV, Toloubeydokhti T, Lawson MA, Garzo G, Duleba AJ, Chang RJ. Individual 17- hydroxyprogesterone responses to hCG are not correlated with follicle size in polycystic ovary syndrome. J Endocr Soc. 2019;3(4):687–698.
- 37. Richards JS, Ren YA, Candelaria N, Adams JE, Rajkovic A. Ovarian follicular theca cell recruitment, differentiation, and impact on fertility: 2017 update. Endocr Rev. 2018;39(1):1–20.
- 38. Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994;79(4):1158–1165.
- 39. Gilling-Smith C, Story H, Rogers V, Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1997;47(1):93–99.
- 40. Crawford TJ, Crowther CA, Alsweiler J, Brown J. Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. Cochrane Database of Systematic Reviews. 2015 DOI: 10.1002/14651858.CD011507.pub2.
- 41. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8:417–23.
- 42. Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, et al. Modulatory role of D-chiroinositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014;30:438–43.
- 43. La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A. The menstrual cycle regularization following Dchiro- inositol treatment in PCOS women: A retrospective study. Gynecol Endocrinol. 2015;31:52-6.
- 44. Piomboni P, Focarelli R, Capaldo A, Stendardi A, Cappelli V, Cianci A, et al. Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: The effect of inositol and metformin. J Assist Reprod Genet. 2014;31:1269-76
- 45. Jamilian M, Mansury S, Bahmani F, Heidar Z, Amirani E, Asemi Z. The effects of probiotic and selenium cosupplementation on parameters of mental health, hormonal profiles, and biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome. J Ovarian Res. 2018 Sep 14;11(1):80.
- 46. Dastorani M, Aghadavod E, Mirhosseini N, Foroozanfard F, Zadeh Modarres S, Amiri Siavashani M, Asemi Z. The effects of vitamin D supplementation on metabolic profiles and gene expression of insulin and lipid metabolism in infertile polycystic ovary syndrome candidates for in vitro fertilization. Reprod Biol Endocrinol. 2018 Oct 4;16(1):94. doi: 10.1186/s12958-018-0413-3.
- 47. Kazemi M, McBreairty LE, Chizen DR, Pierson RA, Chilibeck PD, Zello GA. A Comparison of a Pulse- Based Diet and the Therapeutic Lifestyle Changes Diet in Combination with Exercise and Health Counselling on the Cardio-Metabolic Risk Profile in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients. 2018 Sep 30;10(10):1387.
- 48. Arentz S, Smith CA, Abbott J, Fahey P, Cheema BS, Bensoussan A. Combined Lifestyle and Herbal Medicine in Overweight Women with Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. Phytother Res. 2017 Sep;31(9):1330-1340. doi: 10.1002/ptr.5858.
- 49. Borzoei A, Rafraf M, Asghari-Jafarabadi M. Cinnamon improves metabolic factors without detectable effects on adiponectin in women with polycystic ovary syndrome. Asia Pac J Clin Nutr. 2018;27(3):556-563. doi: 10.6133/apjcn.062017.13.
- 50. Pedersen AJT, Stage TB, Glintborg D, Andersen M, Christensen MMH. The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):239-244. doi: 10.1111/bcpt.12874.
- 51. Nordio M, Basciani S, Camajani E. The 40:1 myoinositol/ D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5512-5521. doi: 10.26355/eurrev_201906_18223.
- 52. Ostadmohammadi V, Jamilian M, Bahmani F, Asemi Z. Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome. J Ovarian Res. 2019 Jan 21;12(1):5. doi: 10.1186/s13048-019-0480-x.
- 53. Javed Z, Papageorgiou M, Deshmukh H, Kilpatrick ES, Mann V, Corless L, Abouda G, Rigby AS, Atkin SL, Sathyapalan T. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome. Nutrients. 2019 Jan 17;11(1):188. doi: 10.3390/nu11010188.
- 54. Wang QY, Song Y, Huang W, Xiao L, Wang QS, Feng GM. Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. Chin Med J (Engl). 2016 Apr 20;129(8):883-90. doi: 10.4103/0366-6999.179783.
- 55. Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. BMC Endocr Disord. 2017 Jan 31;17(1):5. doi: 10.1186/s12902-017-0155-9.
- 56. Liang R, Liu Z, Li P, Fan P, Xu L, Sun X, Peng J, Peng X, Zhang M. Kuntai capsules improve glucolipid metabolism in patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2019 Sep;98(39):e16788. doi: 10.1097/MD.0000000000016788.